Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 250

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial

DeLurgio, David B., Crossen, Karl J., Gill, Jaswinder, Blauth, Christopher, Oza, Saumil R., Magnano, Anthony R., Mostovych, Mark A., Halkos, Michael E., Tschopp, David R., Kerendi, Faraz, Taigen, Tyler L., Shults, Christian C., Shah, Manish H., Rajendra, Anil B., Osorio, Jose, Silver, Jonathan S., Hook, Bruce G., Gilligan, David M., Calkins, Hugh · 2020 · Circulation: Arrhythmia and Electrophysiology

Abstract

Background: The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the development of a minimally invasive epicardial/endocardial ablation approach (Hybrid Convergent) to achieve a more comprehensive lesion set with durable transmural lesions. The multicenter randomized controlled CONVERGE trial (Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF) evaluated the safety of Hybrid Convergent and compared its effectiveness to CA for persistent and long-standing persistent AF treatment. Methods: One-hundred fifty-three patients were randomized 2:1 to Hybrid Convergent versus CA. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously failed/intolerant class I/III antiarrhythmic drugs through 12 months. Primary safety was major adverse events through 30 days. CONVERGE permitted left atrium size up to 6 cm and imposed no limits on AF duration, making it the only ablation trial to substantially include long-standing persistent–AF, that is, 42% patients with long-standing persistent–AF. Results: Of 149 evaluable patients at 12 months, primary effectiveness was achieved in 67.7% (67/99) patients with Hybrid Convergent and 50.0% (25/50) with CA ( P =0.036) on/off previously failed antiarrhythmic drugs and in 53.5% (53/99) versus 32.0% (16/50; P =0.0128) respectively off antiarrhythmic drugs. At 18 months using 7-day Holter, 74.0% (53/72) Hybrid Convergent and 55% (23/42) CA patients experienced ≥90% AF burden reduction. A total of 2.9% (3/102) patients had primary safety events within 7 days, and 4.9% (5/102) between 8 and 30 days postprocedure. No deaths, cardiac perforations, or atrioesophageal fistulas occurred. All but one primary safety event resolved. Conclusions: The Hybrid Convergent procedure has superior effectiveness compared to the CA for the treatment of persistent and long-standing persistent atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01984346.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circep.120.009288

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 250

Metadata

Authors
DeLurgio, D. B., Crossen, K. J., Gill, J., Blauth, C., Oza, S. R., Magnano, A. R., Mostovych, M. A., Halkos, M. E., Tschopp, D. R., Kerendi, F., Taigen, T. L., Shults, C. C., Shah, M. H., Rajendra, A. B., Osorio, J., Silver, J. S., Hook, B. G., Gilligan, D. M., & Calkins, H.
Venue
Circulation: Arrhythmia and Electrophysiology
Published
2020-12
Volume
13
Issue
12
Pages
e009288-e009288
ISSN
  • 1941-3084 (ISSN-L)
  • 1941-3149
OpenAlex
W3104047110
Cited by
250
References
3
FWCI
14.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial. https://app.cochat.ai/papers/10.1161/circep.120.009288
The paper
DeLurgio, D. B., Crossen, K. J., Gill, J., Blauth, C., Oza, S. R., Magnano, A. R., Mostovych, M. A., Halkos, M. E., Tschopp, D. R., Kerendi, F., Taigen, T. L., Shults, C. C., Shah, M. H., Rajendra, A. B., Osorio, J., Silver, J. S., Hook, B. G., Gilligan, D. M., & Calkins, H. (2020). Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.120.009288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.